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Abstract 
 
Purpose: Chronic pain is a prominent feature of autosomal dominant polycystic kidney 
disease (ADPKD) that is difficult to treat and manage, often resulting in a decrease in 
quality of life. Understanding the underlying anatomy of renal innervation and different 
etiologies of pain that occur in ADPKD can help to guide proper treatments to manage 
pain. Reviewing the previously studied treatments for pain in ADPKD can help to 
characterize treatment in a stepwise fashion.  
Materials and Methods: We performed a literature search of the etiology and 
management of pain in ADPKD and the anatomy of renal innervation using Pubmed® 
and Embase® from January 1985 to April 2014 with limitations to human studies and 
English language. 
Results: Pain occurs in the majority of patients with ADPKD due to renal, hepatic, and 
mechanical origins. Patients may experience different types of pain, which can make it 
difficult to clinically confirm its etiology. An anatomical and histological evaluation of the 
complex renal innervation helps with an understanding of the mechanisms that can lead 
to renal pain. Understanding the complex nature of renal innervation is essential for 
surgeons to perform a renal denervation procedure. The management of pain in 
ADPKD should be approached in a stepwise fashion. Acute causes of renal pain must 
first be ruled out due to the high incidence in ADPKD. For chronic pain, non-opioid 
analgesics and conservative interventions can be first used before opioid analgesics are 
considered. If pain continues, there are surgical interventions that can target pain 
produced by renal or hepatic cysts. Surgical options include renal cyst decortication, 
renal denervation, and nephrectomy.  
Conclusion: Chronic pain in patients with ADPKD is often refractory to conservative, 
medical, and other non-invasive treatments. There are effective surgical procedures that 
can be implemented when more conservative treatments fail. Laparoscopic cyst 
decortication has been well studied and results in relief of chronic renal pain in the 
majority of patients. In addition, renal denervation has successfully been utilized and 
could be performed concurrently with cyst decortication. Nephrectomy should be 
reserved for patients with intractable pain and renal failure when other modalities have 
failed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
ADPKD is a relatively common disease that has a worldwide prevalence of 1:400 to 
1:10001. Pain is a prominent feature of all types of polycystic kidney disease affecting 
over 60% of patients, and is most commonly located in in the flank, followed by the back 
and abdomen.1, 2 Pain is often present early in the disease process and is the most 
common symptom that leads to a diagnosis of the disease.3 In patients with ADPKD, 
the hardships of living with chronic pain can prevent them from performing both physical 
and social activities, detrimentally affecting their quality of life.4 The difficulty of pain 
management is demonstrated by many patients, with up to 39% of patients being 
somewhat or completely dissatisfied with pain treatment because they are physically 
unable to do what they would like.5 A better understanding of the etiology of pain that 
occurs in ADPKD in addition to the underlying anatomy can help to guide treatment. 
 
Materials and Methods 
We performed a literature search of the etiology and management of pain in ADPKD 
using Pubmed® and Embase® from January 1985 to April 2014 with limitations to 
human studies and English language. Search terms included pain management, chronic 
pain, treatment, therapy, polycystic kidney, autosomal dominant, cyst, hepatic, liver, 
kidney, and renal. References of the studies found were reviewed. Further searches 
were performed using MEDLINE® and Embase® for each relevant treatment of ADPKD 
identified with additional search terms added including analgesics, Alexander 
Technique, tolvaptan, opioids, aspiration, celiac plexus, splanchnic nerves, 
splanchnicectomy, block, ablation, spinal cord stimulation, sclerotherapy,  decortication, 
laparoscopic, marsupialization, denervation, percutaneous, sympathectomy, 
nephrectomy, transplant, and transcatheter arterial embolization. A comprehensive 
review of the literature identified 140 studies involving the presentation of pain and 
symptomatic treatment in ADPKD. Thirty of those studies were selected for this review 
based on appropriate study design, duration of follow up, number of patients, and 
method of measuring pain control. The literature selected consisted of systematic 
reviews, randomized controlled trials, cross-sectional studies, retrospective case series, 
and case reports.  
A literature search was also performed to better delineate the anatomy and 
histology of renal innervation using Pubmed® and Embase® with limitations to English 
language. Search terms included anatomy, histology, renal, kidney, nerve, innervation, 
splanchnic, celiac, sympathetic, autonomic, sensory, and afferent. References of the 
studies found were reviewed and textbooks were consulted for additional information. 
Fifty-four articles of anatomy and histology were reviewed, and 17 were included based 
on the number of samples in the study, method of histopathological sectioning, and 
presence of afferent neural tissue. 
 
Results 
     
Chronic Renal Pain  
Renal cysts can lead to pain in the back, abdomen, and flank region. Patients with 
ADPKD often experience multiple types of pain which can be described as dull, an 
uncomfortable fullness, stabbing, and cramping.3 Chronic pain due to cyst formation 
may also present as a persistent discomfort localized to a small area that is aggravated 
by standing or walking.6 Many patients also experience a sudden onset of pain while 
performing physical activities.4 Renal mechanosensory nerves, which respond to 
changes in pressure, and renal chemosensory nerves, which respond to ischemia or 
alterations of the renal interstitial fluid, have been identified in the kidney.7 Cystic 
compression of the renal capsule and parenchyma can lead to transmission of pain 
through afferent sensory nerve fibers around the renal vasculature, in the 
corticomedullary connective tissue, and in the renal pelvic region.8 Pain is not related to 
kidney size early in the disease process (eGFR>60mL/min/1.73m2) unless the kidneys 
are extremely large with a height adjusted kidney volume greater than 1,000 mL/m.5 
Pain presentation based on cyst size can be variable as some patients with smaller 
cysts can experience severe pain, while other patients with larger cysts remain pain 
free.6 Renal associated pain in ADPKD can present in various ways, making it difficult to 
clinically confirm its etiology. Clinical findings often need to be correlated to diagnostic 
images to confirm the source of the pain.  
 
Mechanical Back Pain 
Cystic enlargement of kidneys can lead to lumbar lordosis, and an asymmetrical cystic 
enlargement of kidneys can cause postural changes of the spine. These mechanisms 
can lead to stress and degeneration of the spine resulting in mechanical back pain. 
Cystic enlargement of the liver can cause mechanical back pain through this same 
mechanism. An observation was made that patients with ADPKD have lumbodorsal 
muscle hypertrophy, giving further evidence of mechanical changes that can occur in 
patients with ADPKD.6 
 
Abdominal Fullness and Early Satiety 
The feeling of abdominal fullness can occur due to cystic expansion of the kidney or 
liver, and is present in 20% of patients with ADPKD.5 Compression on the stomach and 
duodenum can result in decreased appetite and abdominal fullness, leading to a risk of 
malnutrition.5, 6  
 
Chronic Liver Pain in ADPKD 
Hepatic cysts in ADPKD can be identified in up to 94% of patients ages 35-46 years 
through magnetic resonance imaging. The cyst volume and incidence increases with 
age as the disease progresses.9 Although most patients with hepatic cysts are 
asymptomatic, some patients develop abdominal fullness and severe pain. 
Compression on the diaphragm can also lead to shortness of breath. Compared to pain 
from renal cysts, liver cysts can cause pain that is more severe and resistant to 
conservative, medical, and surgical intervention.6 
  
Renal Nerve Anatomy and Histology 
 
Extrinsic Renal Nerves 
The renal plexus is a network of nerve filaments and ganglia that are derived from direct 
branches of the celiac plexus, celiac ganglia, aorticorenal ganglia, thoracic splanchnic 
nerves, the upper lumbar splanchnic nerve, and superior portions of the intermesenteric 
plexus (fig. 1). This has been demonstrated in anatomical dissections of human 
cadavers.10, 11 This pattern has been confirmed using retrograde tracers in various 
animal models, although there is variation in paravertebral and dorsal root ganglia of 
origin.7 
The lesser thoracic splanchnic nerve, derived from the 9th and 10th or 10th and 
11th thoracic paravertebral ganglia, innervates the celiac and aorticorenal ganglia which 
send branches to the renal plexus. The least thoracic splanchnic nerve, derived from 
the 12th thoracic paravertebral ganglia, synapses directly on the renal plexus. The upper 
lumbar splanchnic nerve, derived from the 1st lumbar paravertebral ganglia, sends fibers 
to the intermesenteric plexus as well as branches that synapse directly on the renal 
plexus. Fibers from the superior portion of the intermesenteric plexus also run directly to 
the renal plexus.7, 10-12 
The greater splanchnic nerve may connect to the renal plexus through the 
aorticorenal or celiac ganglia, which was seen in a minority of cadavers. Small 
connections to the renal plexus from the inferior portion of the intermesenteric plexus 
and superior portion of the hypogastric plexus were also found in some cadavers.10 
These connections could not be verified in other dissections.11 
 
Renal Nerve Penetration into the Kidney 
As the renal nerves course toward the kidney, the majority of nerve fibers converge 
around the renal artery and enter the kidney with the renal artery through the hilum (fig. 
2). Nerve fibers from the intermesenteric plexus may join the renal plexus distally at the 
inferior aspect of the main renal artery or segmental arteries near the hilum.10 
Contributions from the inferior intermesenteric plexus or superior hypogastric plexus 
may pass through the gonadal artery and plexus to the superior ureter and inferior 
aspect of the renal pelvis.10, 13 Some renal innervation may occur outside the hilum on 
the medial side of the kidney due to direct connections from the aorticorenal ganglia and 
small nerve fibers branching off the renal plexus.10, 13  
 
Renal Neural Anatomy around the Renal Artery 
The renal plexus has been historically described as running circumferential around the 
renal artery based on cadaveric dissections and renal denervation procedures,10, 11, 14 
Two studies examining histological cross sections of 9 and 40 renal arteries confirms a 
circumferential distribution of nerves around the main renal artery.15, 16 However, there 
are more nerve fibers on the ventral aspect of the main renal artery compared to dorsal 
aspect (11.0±3.5 versus 6.2±3.0 per section, p<0.001). There is a significantly higher 
number of average nerve fibers per section on the proximal renal artery (39.6±16.7) 
compared to the distal renal artery (33.6±13.1) (p=0.01). The average distance of nerve 
fibers to the arterial lumen is greater on proximal versus distal segments (3.40±0.54mm 
versus 2.60±0.77, p<0.001).15  The trend is for a higher nerve density on the ventral 
aspect of the renal artery, with nerve fibers that are more numerous and further from the 
lumen of the artery on more proximal segments. 
The afferent sensory renal nerve fibers are intermixed with sympathetic nerve 
fibers in bundles around the renal artery and begin 0.5mm from the lumen of the 
artery.15, 16 The wall of a renal artery can have a depth up to 0.25mm, based on the 
upper bound 95% confidence interval of the tunica intima and media of the renal artery 
in an elderly subset of patients.17  This suggests that nearly all of the nerve fibers, which 
are at least 0.5mm from the lumen, run outside of the tunica media and are in the tunica 
adventitia and surrounding tissue. Examination of histological cross sections confirms 
the nerves to be in the adventitia and periadventitial fat where nervous tissue can be 
surgically stripped from the renal artery.15 
 
 
Sympathetic Activity and ADPKD 
Elevated sympathetic nerve activity has been implicated in the pathophysiology of 
ADPKD. There is an increase in sympathetic nerve activity in hypertensive patients with 
ADPKD with both normal and impaired renal function.18 The renin-angiotensin-
aldosterone system is activated to a greater extent in hypertensive patients with ADPKD 
compared to patients with essential hypertension.19 Furthermore, angiotensin II can 
enhance epidermal growth factor which promotes cyst formation in the kidney.20 Early 
onset hypertension and increased sympathetic nervous activity could account for the 
high level of cardiovascular morbidity and mortality in ADPKD, with up to 41% of 
patients having left ventricular hypertrophy in an initial demographic study.21 More 
recent evidence suggests the decreasing incidence of left ventricular hypertrophy, now 
found in 3.9% of patients with ADPKD, could be due to improved hypertension control 
earlier in the disease process in addition to the use of renin-angiotensin-aldosterone 
system antagonists.22 The role of renin angiotensin blockade in ADPKD will be better 
understood when the HALT-PKD trial is completed.23 Renal denervation in the rat model 
of ADPKD causes a reduction in cyst size, decrease in blood pressure, and 
improvement of renal function,24 suggesting a further role of sympathetic activity in the 
disease and potential benefit of renal denervation beyond pain control. 
 
Initial Evaluation of Pain 
Evaluation must start with a detailed history and physical examination to determine if 
the pain appears to be acute or chronic in nature. Patients with ADPKD have a higher 
incidence of acute causes of renal pain including nephrolithiasis, cyst hemorrhage, 
pyelonephritis, and cyst infection which must be ruled out.6  
Physical examination may reveal palpable enlarged kidneys or liver. The 
presence of costovertebral angle tenderness upon percussion can result from 
inflammation of the kidney and should the raise suspicion for an acute cause of renal 
pain.   
A ruptured or hemorrhagic cyst may be present when there is an abrupt onset of 
sharp, localized flank pain with associated gross hematuria. Conservative management 
can be started since the hematuria normally resolves within two to seven days.6  An 
infectious source of pain, such as pyelonephritis or cyst infection, should be suspected 
when a patient has a fever and leukocytosis in addition to increasing flank pain. Urine 
and blood cultures must be obtained and proper antibiotics need to be initiated.1 
Surgical intervention or fluid drainage may be necessary if the infection does not 
respond to antibiotics.  
The use of diagnostic imaging may be essential to isolate the source of both 
acute and chronic causes of pain. A CT scan should be used, rather than MRI, if 
nephrolithiasis needs to be ruled out. Positron emission tomography can be utilized to 
identify a cyst that may be infected.25 Once acute causes are ruled out and pain 
appears to be more chronic, evaluation should attempt to differentiate between 
mechanical, hepatic, renal, or other causes of pain. 
 
Chronic Pain Management 
It is important to focus on helping a patient deal with chronic pain and improve 
functionality, rather than setting intangible goals of completely relieving all pain. Initial 
treatment for chronic pain in ADPKD is not specific to the disease and should consist of 
a step-wise approach (fig. 3), starting with conservative treatment and non-opioid 
analgesics that are beneficial to renal, hepatic, and mechanical causes of pain. 
 
Conservative Treatment 
Conservative treatment includes the use of ice, heat, whirlpool, psychobehavioral 
modification techniques, and the Alexander Technique.6, 26 The Alexander Technique 
helps patients understand and modify what postures and movements result in pain. It 
has been shown to be beneficial in the treatment of chronic back pain,27 and 
observations of its use in patients with ADPKD have led to recommendations of 
including it as a treatment option.6 
 
Analgesics 
The National Kidney Foundation recommends acetaminophen as the preferred non-
opioid analgesic for long-term pain management in patients with underlying renal 
diseases. Non-steroidal anti-inflammatory drugs can be used for acute episodes of pain, 
however long-term use is discouraged due to the potential for renal toxicity, and renal 
function should be monitored with long-term use.28 These recommendations should be 
applied to patients with ADPKD since 45% of patients experience renal failure by the 
age of 60.1  
Tramadol, as well as other adjuvant analgesics including clonidine, gabapentin, 
pregabalin, duloxetine, and amitriptyline can be added to acetaminophen to help control 
pain before opioids are implemented.6, 26 If indicated, opioids should be initiated as a 
trial to determine if they are appropriate in treating pain. The initial opioid selected, 
dosing, and titration should be based on the patients past analgesic use and response. 
Patients should be evaluated periodically for effectiveness and side effects of the 
medication. An opioid rotation may need to be implemented if pain is refractory to higher 
doses.29 
Tolvaptan, a vasopressin V2-receptor antagonist, has been shown to cause a 
statistically significant decrease in renal pain in patients with ADPKD, likely through a 
decrease in cystic pressure and fluid production. However, the small amount of pain 
relief compared to placebo (5 versus 7 events per 100 person-years of follow-up, 
p=0.007) in addition to the side effects of polyuria and polydipsia limits the indication of 
its use for pain.30 While tolvaptan is not indicated to treat pain in ADPKD, it shows that 
future medical treatment which limits cyst growth could potentially improve pain control 
in ADPKD. 
 
Autonomic Nerve Block and Spinal Cord Stimulation 
Celiac plexus nerve block is used to control chronic visceral pain and has been 
suggested to be of benefit in ADPKD.6, 26 Anatomy previously discussed suggest that 
this procedure may only block a portion of renal sensory innervation, since the least 
thoracic and lumbar splanchnic nerves do not relay through the celiac plexus. Targeting 
splanchnic nerves would produce a wider blockade of renal sensory outflow compared 
to a blockade of the celiac plexus. Although it has not been documented in ADPKD, 
radiofrequency ablation of the splanchnic nerves was able to provide pain relief in a 
patient with loin pain hematuria syndrome.31 Celiac plexus nerve blocks with 
radiofrequency ablation of the intercostal nerves has been used to provide short term 
pain relief in a patient with ADPKD, followed by the use of spinal cord stimulation for 
longer term pain relief.32 
 
Cyst Aspiration and Ablation 
Cyst aspiration under ultrasound guidance is the least invasive procedure used to 
reduce the size of cysts for relief of pain, however pain recurs in 67% of patients after 
18 months as the cysts reform.33 In conjunction with cyst aspiration, sclerotherapy can 
be added for further reduction in cyst size. These procedures are most useful when 
there are only a few dominant cysts responsible for the patient’s symptoms, which is 
uncommon in ADPKD. There are a variety of sclerosing agents that have been used 
including ethanol, minocycline, and n-butyl cyanoacrylate with iodized oil. There is 
evidence of successful reduction of clinical symptoms with sclerotherapy in 17 out of 21 
patients (81%) with ADPKD at a mean follow up of 28.5 months. All patients had 
between 3 to 6 cysts, which is a low number of cysts for patients with ADPKD.34 
 
Cyst Decortication 
Cyst decortication can relieve pain through releasing pressure on the renal capsule and 
parenchyma in addition to reducing compression on the surrounding tissue. Cyst 
decortication is the most extensively studied procedure for chronic pain relief in ADPKD 
with a review showing successful pain relief in all fifteen studies and evidence of 
sustained pain relief in the majority of patients five years out. Pain relief continues one 
year after the procedure in 80-92% of patients, which slightly decreases over time at 
longer follow up visits.35 A long-term follow up with a mean of 10.9 years found that 8 
out of 12 patients (67%) continued to have greater than 50% pain improvement.36 There 
does not appear to be any improvement in blood pressure control or renal function.35 
Caution is advised in performing laparoscopic cyst decortication (LCD) in patients with 
renal impairment, as decreased preoperative estimated glomerular filtration rate is 
associated with a progression to end stage renal disease after LCD.36 However, there is 
no known causality of this association, and LCD remains a treatment option for pain in 
patients with decreased renal function to preserve remaining function by avoiding 
nephrectomy as an alternative treatment for pain. For LCD to be most effective, almost 
all cysts that are accessible on all surfaces of the kidney must be addressed. The 
kidney will need to be extensively mobilized, and nephropexy may be required at the 
end of the procedure. Laparoscopic ultrasound may be required to ensure that the 
collecting system is not entered and smaller cysts are identified. Patients should be 
counseled that they may experience a temporary increase in pain post-operatively due 
to irritating fluid released from hemorrhagic cysts. 
 
Renal Denervation 
Laparoscopic renal denervation has been performed in an adolescent age group in a 
case series of 4 and 12 patients with ADPKD (mean ages 17 and 12.4 years) who had 
chronic flank pain refractory to narcotics of 6-9/10 on Bieri modified and Wong-Baker 
pain scales.  Division of all nervous tissue near the hilum was performed, followed by 
circumferential dissection of the kidney to divide any nerves that did not course through 
the hilum. All patients were pain free without the need for analgesics at a mean follow 
up of 11.5 and 25.5 months respectively.37, 38 A thoracoscopic approach of renal 
denervation has been performed for pain refractory to narcotics and repeated cyst 
aspirations. Sympathosplanchnicectomy of the sympathetic chain and splanchnic 
nerves was performed, resulting in pain relief the day after the procedure and at a 2 
year follow up with no need for analgesics.39 This approach is being using in a clinical 
trial (NCT00571909) with initial reports of six out of nine patients being pain free without 
analgesics at three month follow up.26 A thorough wide dissection of the renal artery at 
the hilum may need to be performed during a renal denervation procedure in order to 
dissect nerves that may not have run the course of the renal artery. Alternatively, it 
would be safer to perform circumferential renal denervation of the renal artery near its 
origin with care to dissect nerve fibers on the lateral aspect of the aorta that may join the 
renal artery at more distal segments. Division of all tissue on the medial aspect the 
kidney and along the proximal ureter can denervate remaining nerve connections. 
Multiple renal arteries are present in 28% of patients, based on a review of the anatomy 
of renal arteries.40 Renal innervation follows each artery entering the kidney,10 implying 
that renal denervation would need to be performed around each artery. 
Percutaneous transluminal renal denervation was able to relieve pain in a patient 
with ADPKD, and a follow up procedure on the contralateral side was performed due to 
the success.41 The failure of percutaneous transluminal renal denervation to decrease 
systolic blood pressure compared to a sham operation raises some concern for the 
efficacy of this procedure to treat pain, since the sensory nerves lie within the bundles of 
sympathetic fibers targeted with this procedure.42 Renal denervation would not likely be 
beneficial in patients who have mechanical associated pain or are experiencing early 
satiety. However, it could be used in conjunction with LCD or alone when renal cysts 
are and too small or deep for LCD to be beneficial. It is our practice to perform renal 
denervation along with extensive laparoscopic renal cyst decortication in patients with 
refractory renal pain.  
 
Nephrectomy 
Nephrectomy is reserved for treating chronic renal pain in patients with end stage renal 
disease when other treatment modalities have failed. This procedure can be performed 
unilaterally or bilaterally which necessitates the use of dialysis or renal transplantation. 
Bilateral laparoscopic nephrectomy has been shown to decrease visual analog pain 
scores from an average of 6.9 out of 10 preoperatively to 0.5 at three month follow up in 
18 patients studied,43 with evidence of long-term pain relief at 31 months in a separate 
study.44  The laparoscopic approach is generally preferred over an open procedure due 
to decreased blood loss, shorter recovery, and decreased pain.44 Patients with 
extremely large kidneys with a volume greater than 3500cc are at an increased risk of 
conversion to an open procedure, thus open nephrectomy may initially be considered in 
these patients.43 Unilateral nephrectomy with renal transplantation does not increase 
morbidity compared to renal transplantation alone in patients with ADPKD. Renal 
transplantation with unilateral nephrectomy followed by laparoscopic unilateral 
nephrectomy has a better perioperative outcome compared to renal transplantation 
followed by bilateral laparoscopic nephrectomy.45 Unpublished data from our institution 
suggests that transplant with concurrent unilateral nephrectomy in patients with ADPKD 
results in a greater decrease in the number of antihypertensive medications needed 
compared to transplant alone. 
 
Transcatheter Arterial Embolization 
Transcatheter arterial embolization of distal branches of the renal artery results in a 
reduction in renal volume by 47% after one year after treatment.46 Reduction in renal 
volume decreases compression on surrounding organs that can reduce abdominal 
fullness, discomfort, and early satiety. This procedure can be used in patients with end 
stage renal disease who have failed other treatment modalities and are poor surgical 
candidates for nephrectomy.26 Symptomatic hepatic cysts can also be reduced by 
embolization of hepatic segments involved. 
 
Hepatic Cyst Treatment 
There are a variety of surgical approaches that can be performed for pain associated 
with hepatic cysts including cyst fenestration, cyst fenestration with hepatic resection, 
liver transplantation, and transcatheter arterial embolization. Cyst fenestration alone can 
be used when there are a few superficial dominant cysts, and the addition of hepatic 
resection can be used in highly symptomatic patients if at least one hepatic sector can 
be preserved. Liver transplantation is indicated if a single hepatic sector cannot be 
preserved, but it may be difficult to obtain a liver for transplantation since the indication 
in these patients is usually for symptoms and not for liver failure. While morbidity can be 
up to 63% using hepatic resection with cyst fenestration, long-term success at a follow 
up of 9 years has been demonstrated with 75% of patients showing a normalized or 
improved functionality measured by the Eastern Cooperative Oncology Group 
Performance Status.47   
 
Conclusions 
The presentation of pain in patients with ADPKD can be variable, due to the numerous 
mechanisms that can generate pain in this patient population. Knowing the etiology of 
pain can help a physician select an appropriate treatment. There are a variety of 
conservative, medical, and non-invasive procedures that can be used to treat chronic 
pain in ADPKD.  However, pain is often difficult to control and may be refractory to 
conservative measures. In this event, there are surgical procedures that can be 
implemented to provide reliable relief. Laparoscopic cyst decortication has been 
extensively studied and proven to provide long-term pain relief in the majority of 
patients. Renal denervation is a procedure that has been highly successful in the 
pediatric population, and could be performed in addition to laparoscopic cyst 
decortication. Finally, nephrectomy can be used in patients with end stage renal disease 
when other treatment modalities have failed. 
FIGURE LEGEND 
 
Figure 1. Diagram of extrinsic renal innervation based on human cadaveric dissections 
and animal models. The lighter text and arrows represents nerve conections found in 
only a minorty of human cadavers. 7, 10-12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Illustration of renal innervation, based on the dissections of Mitchell GA.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Flowchart of evaluation and treatment of chronic pain in ADPKD. SCS: spinal 
cord stimulation, TAE: transcatheter arterial embolization  
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